Ariya Bio

Last week, our co-founder Jan Nelis attended the Sachs Associates 24th Annual Biotech in Europe Forum in Basel. We had the opportunity to present an update on Ariya Bio's progress and plans and engage with investors, partners, and peers. If you want to learn more about how we turn blood stem cells into living drug factories, reach out to us. #genetherapy #biotech #CRISPR #startup

Exciting News: 💥 Ariya Bio has been accepted into the renowned Innosuisse Core Coaching program. After successfully completing the initial coaching program during the past year, we are now advancing to the next stage. This gives us access to valuable resources and experienced coaches to further refine our strategy. We want to especially thank Michael Wacker, our lead coach, for his invaluable and continued advice. We look forward to many engaging and enriching discussions. (https://lnkd.in/dVXu2dk) #genetherapy #biotech #CRISPR #startup

The newly published FDA draft guidance on the Platform Technology Designation Programs is a big leap for the Cell and Gene Therapy industry. Also, for Ariya Bio , this draft guidance is greatly informative and promising. It outlines a path on how to accelerate the development of curative treatments based on our novel CRISPR-Cas based gene therapy platform. #genetherapy #CRISPRCAS #platform #CGT

Last week, our founder Jan Nelis had the fantastic opportunity to exchange and engage with innovators and facilitators in the cell and gene therapy space at the Advanced Therapies Congress in London. We presented an update on our best-in-class lead programs in sickle cell disease and β-thalassemia and discussed our platform's potential to develop cures for multiple inherited disorders. Learn more about how we combine two powerful technologies, hematopoietic stem cell therapy and CRISPR Cas gene editing, to develop transformative genomic medicines at www.ariyabio.ch

We're thrilled to welcome Amir Taheri-Ghahfarokhi to the team at Ariya Bio as our new Research Lead and co-founder! With his past experiences in both large and small biotech companies, Amir brings extensive expertise in CRISPR Cas gene editing and DNA repair pathways, which will be invaluable as we work to bring curative treatments to patients in need. Join us in congratulating Amir and learn more about our mission to cure hemoglobinopathies at https://www.ariyabio.ch/

It was truly amazing to engage with RNA therapeutics enthusiasts and innovators at yesterday's Swiss RNA Therapeutics Summit in Bern. Our Co-Founder, Jan Nelis, shared some insights into the exciting work we do at Ariya Bio. Stay tuned for future updates on our Hemoglobinopathy programs and beyond. We want to thank NCCR RNA & Disease for this amazing opportunity and the continued support provided to researchers and entrepreneurs. #geneediting #biotech #crispr #genetherapy #redbloodcells #ariyabio

Join us at the CRISPR Medicine News Conference in April, where our Co-Founder Jan Nelis will be giving an update on Ariya Bio`s progress.

Recently our work was featured in CRISPR Medicine News. Thank you, Karen O'Hanlon Cohrt, PhD, for this fantastic article which gives an overview of our journey so far and future plans. Help us bring a cure to diseases that really need one! #geneediting #biotech #crispr #genetherapy #ariyabio